C
Charles D. Blanke
Researcher at University of British Columbia
Publications - 106
Citations - 17049
Charles D. Blanke is an academic researcher from University of British Columbia. The author has contributed to research in topics: Imatinib mesylate & Medicine. The author has an hindex of 33, co-authored 87 publications receiving 16100 citations. Previous affiliations of Charles D. Blanke include University of Michigan & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more
TL;DR: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Journal ArticleDOI
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz,John Cox,Charles D. Blanke,Lee S. Rosen,Louis Fehrenbacher,Malcolm J. Moore,Jean A. Maroun,Stephen P. Ackland,Paula K. Locker,Nicoletta Pirotta,Gary Elfring,Langdon L. Miller +11 more
TL;DR: In this paper, the authors compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of leucocil as first-line therapy for metastatic colorectal cancer.
Journal ArticleDOI
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael Heinrich,Christopher L. Corless,George D. Demetri,Charles D. Blanke,Margaret von Mehren,Heikki Joensuu,Laura McGreevey,Chang Jie Chen,Annick D. Van den Abbeele,Brian J. Druker,Beate Kiese,Burton L. Eisenberg,Peter J. Roberts,Samuel Singer,Christopher D.M. Fletcher,Sandra Silberman,Sasa Dimitrijevic,Jonathan A. Fletcher +17 more
TL;DR: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib.
Journal ArticleDOI
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo,Karla V. Ballman,Cristina R. Antonescu,Robert G. Maki,Peter W.T. Pisters,George D. Demetri,Martin E. Blackstein,Charles D. Blanke,Margaret von Mehren,Murray F. Brennan,Shreyaskumar Patel,Martin D. McCarter,Jonathan Polikoff,Benjamin R. Tan,Kouros Owzar +14 more
TL;DR: Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.
Journal ArticleDOI
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Michael Heinrich,Christopher L. Corless,Charles D. Blanke,George D. Demetri,Heikki Joensuu,Peter J. Roberts,Burton L. Eisenberg,Margaret von Mehren,Christopher D.M. Fletcher,Katrin Sandau,Karen McDougall,Wen-Bin Ou,Chang Jie Chen,Jonathan A. Fletcher +13 more
TL;DR: Using RNAi technology, it is demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of critical downstream signaling pathways, which has implications for future approaches to the growing problem ofImatinib resistance in patients with advanced GISTs.